Sample review output · source-linked draft
01Treatment period
STEP 1 compared once-weekly semaglutide with placebo, both alongside lifestyle intervention, in adults with overweight or obesity without diabetes. At 68 weeks, average weight reduction was greater in the semaglutide arm. The study also reported gastrointestinal adverse events. [1]
02After withdrawal
The extension followed a subset after both study treatment and lifestyle intervention ended. Weight regain was observed during the following year. These exploratory follow-up results concern selected completers and should not be treated as an independent randomized comparison of withdrawal strategies. [2]
03Synthesis and limits
Treatment-period weight change and maintenance after withdrawal answer different questions. Read them together while preserving the difference between the randomized trial and its exploratory extension. These two reports alone cannot establish a complete evidence base, comparative effectiveness against other drugs or an individual treatment recommendation. [1][2]